The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment

Launched by ASSIUT UNIVERSITY · Mar 22, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of white blood cells, called T-follicular helper and T-follicular regulatory cells, in patients who have autoimmune hemolytic anemia. This condition happens when the body's immune system mistakenly attacks its own red blood cells, leading to anemia. The study aims to understand how these cells change before and after treatment, which could help improve future therapies for this condition.

To participate in this trial, individuals must be diagnosed with autoimmune hemolytic anemia, either as a primary condition or secondary to another illness, and cannot be currently receiving any treatment. Unfortunately, pregnant or breastfeeding women, those on certain medications like steroids or immunosuppressants, and patients with specific blood disorders or those who have had blood transfusions are not eligible to join. If you qualify and choose to participate, you will help researchers learn more about this disease and how to better manage it for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed as autoimmune hemolytic anemia, primary or secondary, male or female, any age but not on treatment
• Exclusion Criteria:
• • Pregnancy or breast-feeding women
• • Patients treated with corticoids or immunosuppressant.
• • Patients with hematological malignance.
• • Patients with alloimmune hemolytic anemia as ABO incompatibility or transplant patients